MARLBOROUGH, Mass. and
IRVINE, Calif., Jan. 15, 2019 /PRNewswire/ -- Boston Scientific
Corporation (NYSE: BSX) and Edwards Lifesciences Corporation
(NYSE: EW) today announced that the companies have reached an
agreement to settle all outstanding patent disputes between the
companies in all venues around the world. All pending cases or
appeals in courts and patent offices between the two companies will
be dismissed, and the parties will not litigate patent disputes
related to current portfolios of transcatheter aortic valves,
certain mitral valve repair devices, and left atrial appendage
closure devices. Any injunctions currently in place will be
lifted.
Under the terms of the agreement, Edwards has made a one-time
payment to Boston Scientific of $180
million. No further royalties will be owed by either
party under the agreement. All other terms remain
confidential.
About Boston Scientific
Boston Scientific transforms lives through innovative medical
solutions that improve the health of patients around the
world. As a global medical technology leader for more than 35
years, we advance science for life by providing a broad range of
high performance solutions that address unmet patient needs and
reduce the cost of healthcare. For more information,
visit www.bostonscientific.com and connect
on Twitter and Facebook.
About Edwards Lifesciences
Edwards Lifesciences,
based in Irvine, Calif., is the
global leader in patient-focused medical innovations for structural
heart disease, as well as critical care and surgical monitoring.
Driven by a passion to help patients, the company collaborates with
the world's leading clinicians and researchers to address unmet
healthcare needs, working to improve patient outcomes and enhance
lives. For more information, visit www.Edwards.com and follow us on
Twitter @EdwardsLifesci.
Contacts
Boston Scientific
Trish Backes
Media Relations
651-582-5887 (office)
Trish.Backes@bsci.com
Susie Lisa, CFA
Investor Relations
(508) 683-5565 (office)
investor_relations@bsci.com
Edwards Lifesciences
Media Contact: Sarah Huoh, 949-250-5070
Investor Contact: David K. Erickson,
949-250-6826
View original
content:http://www.prnewswire.com/news-releases/boston-scientific-edwards-lifesciences-agree-to-global-litigation-settlement-300778187.html
SOURCE Boston Scientific Corporation; Edwards Lifesciences
Corporation